- Home
- PPBT vs BFRI Comparison
PPBT vs BFRI Comparison
Compare PPBT & BFRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PPBT
- BFRI
- Stock Information
- Founded
- PPBT 2010
- BFRI 1997
- Country
- PPBT Israel
- BFRI United States
- Employees
- PPBT N/A
- BFRI N/A
- Industry
- PPBT Biotechnology: Pharmaceutical Preparations
- BFRI Biotechnology: Pharmaceutical Preparations
- Sector
- PPBT Health Care
- BFRI Health Care
- Exchange
- PPBT Nasdaq
- BFRI Nasdaq
- Market Cap
- PPBT 7.1M
- BFRI 7.5M
- IPO Year
- PPBT N/A
- BFRI 2021
- Fundamental
- Price
- PPBT $2.73
- BFRI $0.83
- Analyst Decision
- PPBT Strong Buy
- BFRI Strong Buy
- Analyst Count
- PPBT 1
- BFRI 1
- Target Price
- PPBT $33.00
- BFRI $7.00
- AVG Volume (30 Days)
- PPBT 16.2K
- BFRI 80.1K
- Earning Date
- PPBT 05-20-2025
- BFRI 05-14-2025
- Dividend Yield
- PPBT N/A
- BFRI N/A
- EPS Growth
- PPBT N/A
- BFRI N/A
- EPS
- PPBT N/A
- BFRI N/A
- Revenue
- PPBT N/A
- BFRI $37,321,000.00
- Revenue This Year
- PPBT N/A
- BFRI $18.57
- Revenue Next Year
- PPBT N/A
- BFRI $20.17
- P/E Ratio
- PPBT N/A
- BFRI N/A
- Revenue Growth
- PPBT N/A
- BFRI 9.54
- 52 Week Low
- PPBT $2.00
- BFRI $0.65
- 52 Week High
- PPBT $20.60
- BFRI $2.22
- Technical
- Relative Strength Index (RSI)
- PPBT 51.95
- BFRI 48.57
- Support Level
- PPBT $2.67
- BFRI $0.76
- Resistance Level
- PPBT $2.75
- BFRI $0.87
- Average True Range (ATR)
- PPBT 0.21
- BFRI 0.07
- MACD
- PPBT 0.04
- BFRI 0.01
- Stochastic Oscillator
- PPBT 67.19
- BFRI 81.02
About PPBT Purple Biotech Ltd.
Purple Biotech Ltd is a clinical-stage company focused on advancing first-in-class therapies to overcome tumor immune evasion and drug resistance, and to create treatments for people with cancer. Its oncology pipeline includes NT219: A dual inhibitor, small molecule that simultaneously targets Insulin Receptor Substrate 1 and 2 (IRS1/2) and Signal Transducer and Activator of Transcription (STAT3), two survival signal transduction pathways driving the development of cancer drug resistance. and CM24: is a humanized monoclonal antibody designed to block the interactions of Carcinoembryonic Antigen Related Cell Adhesion Molecule 1 (CEACAM1), a glycoprotein that plays a key role in immune regulation, cell adhesion, and tumor progression, CAPTN3.
About BFRI Biofrontera Inc.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions.